Covering chemically synthesized compounds, delivery mechanisms,
screeners & protocols and new drug formulations.
FULLY APPROVED PSILOCYBIN
Cybin aims to become one of the first life sciences companies to
launch a fully approved psilocybin product targeting depression.(2)(3)
Approx $10M successfully raised thus far from Seed and Series-A round.
Strategic shareholder base with long term investment thesis including
biotech funds and former heads of top fortune 100 CPG companies.
Has run multiple clinical trials and facilitated over C$1B in pharma sales.
To attain intellectual property, capabilities and revenue that
strategically align with the business(2)
Wholly-owned subsidiary of Cybin corp.
SERENITY LIFE SCIENCE INC.
Wholly-owned subsidiary of cybin corp.
A Phase 2, Randomized, Parallel Group, Bioequivalence (BE) Study of Psilocybin 1 mg, 3 mg, 5 mg and 7 mg administered with sublingual film to 25 mg Oral Capsule Followed by Placebo-Controlled Safety and Efficacy Trial with Selected Dose in Patients with Major Depressive Disorder (MDD).